資源描述：
《洛鉑、順鉑分別聯(lián)合足葉乙甙治療老年小細(xì)胞肺癌對(duì)照研究.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。
1、258vo1．21No．4武警后勤學(xué)院學(xué)報(bào)(醫(yī)學(xué)版)第21卷第4期Apr．2012JournalofLogisticsUniversityofCAPF(MedicalSciences)2012年4月doi：lO．3969~．issn．2095—3720．2012．04．O11洛鉑、順鉑分別聯(lián)合足葉乙甙治療老年小細(xì)胞肺癌對(duì)照研究齊曉倩，魏長宏，武貴存。，高柯，杜曉杰(1．山東省公安消防總隊(duì)醫(yī)院，山東濟(jì)南250102；2．武警山東總隊(duì)醫(yī)院腫瘤血液科，山東濟(jì)南250014)摘要：【目的】評(píng)估洛鉑(1obaplatin，LB
2、P)聯(lián)合足葉乙甙(etoposide，VP一16)與順鉑(cisplatin，DDP)聯(lián)合足葉乙甙治療老年小細(xì)胞肺癌的近期療效和毒性反應(yīng)。【方法156例老年小細(xì)胞肺癌(smallcelllungcancer，SCLC)患者隨機(jī)分為洛鉑聯(lián)合足葉乙甙的LE組(28例)和順鉑聯(lián)合足葉乙甙的EP組(28例)。21d為1周期，連用2個(gè)周期后評(píng)價(jià)近期療效。每周評(píng)估毒性反應(yīng)?！窘Y(jié)果】LE組和EP組有效率(RR)分別為71％和68％，疾病控制率(DCR)分別為89％和86％，均無顯著性差異fP>0．05)。兩組骨髓抑制無顯著性差異(
3、P>0．05)；消化道反應(yīng)LE組和EP組分別為21％和50％，有顯著性差異(P<0．05)。【結(jié)論】LE和EP均為治療老年SCLC的有效方案，療效相當(dāng)，LE組消化道反應(yīng)較EP組輕，故LE組患者耐受性更好，特別適合老年患者和曾接受過DDP聯(lián)合化療方案的復(fù)治患者。關(guān)鍵詞：小細(xì)胞肺癌；老年人；足葉乙甙；洛鉑；順鉑【文章編號(hào)】2095—3720(2012)04—0258—04【中圖分類號(hào)】R64【文獻(xiàn)標(biāo)識(shí)碼】AArandomizedcomparativestudyofIobaplatinandcisplatincombine
4、dwithetoposideforsmallcelllungcancerinelderpatientsQIXiao-qian，WEIChang-hong，WUGui-cun，GAOKe，DUXiao-jie(TheFireCorpsHospitalofShandongProvince，Jinan250102，China)Abstract：【Objective】Toobservetheshort—termclinicaleficacyandthesideeffectsofLE(1obaplatinandetoposid
5、e)andEP(cisplatinandetoposide)regimensforadvancedsmallcelllungcancer(SCLC)inelderpatients．【Methods】Atotalof56easesofadvancedsmallcelllungcancerwererandomizedintoLEgroup(28patients)andEPgroup(28patients)accordingtothehospitaldiagnosis．Twoprogramswererepeatedever
6、y21daysand2cycles．Theshort—termclinicaleficacyandthesideeffectsoftwogroupswereevaluatedeveryweek．【Results]Theresponserateinexperimentgroupandcontrolgroupwere71％and68％respectively，anddiseasecontrolratewere89％and86％respectively．whereasalltheobservedeffectshadnosi
7、gnificance(P>0．05)．Theside—effectsweremainlymyleosuppressionwithnostatisticdiferences(P>0．05)．However．thesideeffectsofgastrointestinalreactioninthetwogroupswere21％and50％respectively，withobviousstatisticdiference(P<0．05)．【Conclusion】LEandEPregimenshavesimilartot
8、alefectiverateandsideeffectsinpatientswithSCLC．Thereisnosignificantsurvivaladvantagefortheprogramoflobaplatinandetoposideascomparedwiththeonewithcisplatinandetoposide，butthe
